Today’s reaction (down 13% as I type this) seems a bit overdone to me. Yesterday’s earnings weren’t a grand slam but they weren’t exactly bad either. Earnings declined while sales improved. Yes, the market is wounded, tech is taking a beating, ISRG is expensive, and the future is ever-uncertain, but it’s not like they didn’t beat estimates again.
I think a few years from now this may look like a buying opportunity – but I’ve been very wrong before. Still long and holding.
Today’s reaction (down 13% as I type this) seems a bit overdone to me
on the conference call 4/22. True, they did beat estimates, but the warning going forward is investment capital and procedure case loads that the sales force is predicting.
“we actually think system placements may decelerate further in the U.S. as most of the procedure growth comes from general surgery volumes”
Morningstar
Going forward I believe that the ramp up in peripheral vascular procedures is a growth avenue over surgical robotic systems for now. I’m not trying to sell a particular stock, but I have some in mind.